Danaher Corp (DHR)

Industry Diagnostics & Research

This stock can be held in an Investment ISA and an Investment Account

Sell

$226.02

Buy

$227.09

arrow-down$-6.04 (-2.60%)

Prices updated at 13 Dec 2025, 00:59 EST

Prices minimum 15 mins delay

Prices in USD

Danaher Corp designs, manufactures and markets professional, medical, industrial and commercial products and services. It markets its products under the brand of Beckman Coulter, Aperio, Dexis, Chemtreat and others.

S&P 500

-1.07%

NYSE

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Diagnostics & Research

Chairman

Mr. Steven M. Rales

CEO

Mr. Rainer M. Blair

Most recent earnings

31 Dec 2024

Fiscal year end

31 Dec 2024

Employees

63,000

Head office

2200 Pennsylvania Avenue, North West

Washington

United States

20037-1701

+1 202 828-0850

investor.relations@danaher.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Mr. John T. Schwieters Independent Director	0.15m
Mr. Matthew R. McGrew Executive Vice President and Chief Financial Officer	0.99m
Mr. Matthew E. Gugino Vice President, Corporate FP&A and Group Chief Financial Officer, Life Sciences Innovations businesses	-
Mr. Brian W. Ellis Senior Vice President	0.80m
Mr. Charles W. Lamanna Independent Director	-
Mr. Alan G. Spoon, J.D. Independent Director	-
Ms. Linda Hefner Filler Lead Independent Director	0.19m
Mr. Mitchell P. Rales Director	-
Mr. Steven M. Rales Chairman of the Board	-
Mr. Daniel A. Raskas Senior Vice President, Corporate Development	-
Dr. Elias A. Zerhouni, M.D. Independent Director	-
Ms. Teri L. List-Stoll Independent Director	0.13m
Mr. R. Bradley Gray Senior Vice President, Strategic Development	-
Mr. Rainer M. Blair Director, President and Chief Executive Officer	1.35m
Dr. Jose-Carlos Gutierrez-Ramos, PhD Senior Vice President and Chief Scientific Officer	0.86m
Mr. Feroz Dewan Independent Director	-
Professor Raymond C. Stevens, PhD Independent Director	-
Dr. Jessica L. Mega, M.D.,M.P.H. Independent Director	0.13m
Mr. A. Shane Sanders Independent Director	-
Mr. Christopher M. Bouda Vice President and Chief Accounting Officer	-
Ms. Georgeann F. Couchara Senior Vice President, Human Resources	0.73m
Mr. Christopher Paul Riley Executive Vice President	-
Ms. Julie A. Sawyer Montgomery Executive Vice President	-

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
Vanguard Group Inc	60,769,587
BlackRock Inc	52,300,038
JPMorgan Chase & Co	37,284,060
State Street Corp	27,208,726
Vanguard Investments Australia Ltd	20,600,042

Director dealings

Date chevron-l-regular chevron-r-regular	Action
25 Nov 2024	-
26 Nov 2024	-
26 Nov 2024	-
26 Nov 2024	-
21 Nov 2024	-
21 Nov 2024	-
21 Nov 2024	-
15 Nov 2024	-
25 Oct 2024	-
25 Oct 2024	-
25 Oct 2024	-
25 Oct 2024	-
25 Oct 2024	-
25 Oct 2024	-
25 Oct 2024	-
25 Oct 2024	-
26 Aug 2024	-
01 Aug 2024	-
01 Aug 2024	-
01 Aug 2024	-

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.